Characterization and outcome of "hard to mobilize"' lymphoma patients undergoing autologous stem cell transplantation

Leukemia & Lymphoma
M W SugrueJ S Moreb

Abstract

A "hard to mobilize" patient was defined as one in whom >or= 1x10(6) CD 34+ cells/kg cannot be obtained after two consecutive large volume aphereses. Forty-four consecutive Hodgkin's and non-Hodgkin's lymphoma patients who underwent autologous peripheral blood stem cell (PBSC) transplant treatment between June 1996 and June 1998 were included in this study. Twenty-one patients (48%) met the definition of "hard to mobilize" (Group I). All the rest of the patients (n=23) were the good mobilizers (Group II). The initial mobilization protocol for most patients was 10 microg/kg of G-CSF alone for both groups. For Group I, 7/21 (33%) patients were unable to achieve a minimal dose of >or= 1x10(6) CD34+ cells/kg even after a second mobilization attempt and/or bone marrow (BM) harvest (n=5). Overall, 11/21 (52%) required an additional mobilization and/or BM harvest. Only 3/21 (14%) patients were able to meet the target cell dose of >or= 2.5x10(6) CD34+ cells/kg (median of 4 apheresis). In contrast, 87% of Group II achieved the target dose with a median of 2 aphereses. Predictors of poor mobilization were greater than two prior treatment regimens (p=0.038) and the WBC count (<25,000/microL) on the first day of apheresis (p=0.053). Ninete...Continue Reading

References

Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M JonesD C Linch
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L Passos-CoelhoN E Davidson
Jun 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BeyerW Stieger
Oct 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W BensingerC Weaver
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J WattsD C Linch
May 8, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·W H FlemingJ P McKearn
May 25, 1999·Bone Marrow Transplantation·J M WaplesJ Wingard

❮ Previous
Next ❯

Citations

Jun 10, 2008·Current Opinion in Hematology·Louis M Pelus
Apr 24, 2004·Transfusion·Michael KoenigsmannAstrid Franke
Feb 7, 2007·Future Oncology·Amanda F CashenJohn DiPersio
Aug 22, 2012·Leukemia & Lymphoma·Kirsten Herbert, David Ritchie
Dec 11, 2007·Leukemia & Lymphoma·Mark R Litzow
Jan 27, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Ilhami BerberMustafa Ozgul
Aug 10, 2012·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Caroline Pinto Rebello LacativaAngelo Maiolino
Jun 16, 2012·Immunology Letters·Sara M Rankin
Apr 7, 2012·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Giovanna AndreolaDaniele Laszlo
Oct 25, 2011·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·F BijouF Nicolini
Jun 1, 2011·Experimental Hematology·Mohamad Mohty, Anthony D Ho
Jan 10, 2008·European Journal of Haematology·Esa Jantunen, Taru Kuittinen
Feb 17, 2006·European Journal of Haematology·Lara MalerbaGiuseppe Visani
Jun 24, 2015·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Hakan GokerYahya Buyukasik
Feb 11, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stefan Fruehauf, Guido Tricot
Nov 21, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Patrick WuchterAnthony D Ho
Aug 30, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Iskra PusicJohn F DiPersio
Jan 27, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Patrick StiffGary Calandra
Jan 14, 2009·Bone Marrow Transplantation·W BensingerJ M McCarty
Jan 17, 2014·Journal of Korean Medical Science·Ki Woong SungDae Won Kim
Mar 14, 2003·Bone Marrow Transplantation·A Kessinger, J G Sharp
Mar 23, 2004·Bone Marrow Transplantation·T KuittinenE Jantunen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.